{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T01:23:03Z","timestamp":1785288183754,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013050","name":"New England Research Institutes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015831","name":"Radius Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015831","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003358","name":"Gedeon Richter","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003358","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.fertnstert.2018.10.012","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T23:08:50Z","timestamp":1544137730000},"page":"240-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Vilaprisan in women with uterine fibroids: the\u00a0randomized phase 2b ASTEROID 1 study"],"prefix":"10.1016","volume":"111","author":[{"given":"Linda D.","family":"Bradley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhbir S.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6516-1444","authenticated-orcid":false,"given":"Kristina","family":"Gemzell-Danielsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Petersdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Groettrup-Wolfers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Zvolanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2315-9148","authenticated-orcid":false,"given":"Christian","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2018.10.012_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6874-12-6","article-title":"Prevalence,\u00a0symptoms and management of uterine fibroids: an international\u00a0internet-based survey of 21,746 women","volume":"12","author":"Zimmermann","year":"2012","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib2","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/1471-0528.14640","article-title":"Epidemiology of uterine fibroids: a systematic review","volume":"124","author":"Stewart","year":"2017","journal-title":"BJOG"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1701-2163(15)30338-8","article-title":"The management of uterine leiomyomas","volume":"37","author":"Vilos","year":"2015","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence","volume":"188","author":"Baird","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1590\/0102-311X00025413","article-title":"Does life-course socioeconomic position\u00a0influence racial inequalities in the occurrence of uterine leiomyoma? Evidence from the Pro-Saude Study","volume":"30","author":"Boclin Kde","year":"2014","journal-title":"Cad Saude Publica"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib6","doi-asserted-by":"crossref","first-page":"319.e1","DOI":"10.1016\/j.ajog.2013.07.017","article-title":"The impact of uterine leiomyomas: a national survey of affected women","volume":"209","author":"Borah","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jpsychores.2014.12.016","article-title":"Beyond the physical: a qualitative assessment of the burden of symptomatic\u00a0uterine fibroids on women's emotional and psychosocial health","volume":"78","author":"Ghant","year":"2015","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib8","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1089\/jwh.2013.4334","article-title":"The burden of uterine fibroids for African-American women: results of a national survey","volume":"22","author":"Stewart","year":"2013","journal-title":"J\u00a0Womens Health (Larchmt)"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib9","doi-asserted-by":"crossref","first-page":"h4887","DOI":"10.1136\/bmj.h4887","article-title":"Fibroids: diagnosis and management","volume":"351","author":"Lumsden","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib10","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/0029-7844(95)00252-M","article-title":"Rate of hospitalization for gynecologic disorders among reproductive-age women in the United States","volume":"86","author":"Velebil","year":"1995","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib11","doi-asserted-by":"crossref","first-page":"541.e1","DOI":"10.1016\/j.ajog.2009.12.013","article-title":"Inpatient hospitalization for gynecologic disorders in the United States","volume":"202","author":"Whiteman","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib12","first-page":"327","article-title":"Total laparoscopic hysterectomy (TLH): results at a tertiary referral hospital","volume":"80","author":"Cortes Flores","year":"2012","journal-title":"Ginecol Obstet Mex"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib13","first-page":"229","article-title":"Hysterectomy rates in the United States 1990\u20131997","volume":"99","author":"Farquhar","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib14","article-title":"Radiofrequency ablation for treatment of symptomatic uterine fibroids","author":"Jones","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00006250-199404000-00011","article-title":"Hysterectomy in the United States, 1988\u20131990","volume":"83","author":"Wilcox","year":"1994","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib16","doi-asserted-by":"crossref","first-page":"e0149631","DOI":"10.1371\/journal.pone.0149631","article-title":"Medical therapies for uterine fibroids\u2014a systematic review and network meta-analysis of randomised controlled trials","volume":"11","author":"Gurusamy","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib17","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.fertnstert.2016.11.027","article-title":"Rewriting the script: time to rethink the indications for myoma surgery","volume":"107","author":"Donnez","year":"2017","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib18","first-page":"877","article-title":"The conservative and\u00a0interventional treatment of fibroids","volume":"111","author":"Boosz","year":"2014","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ogc.2012.09.005","article-title":"The impact and management of fibroids for fertility: an evidence-based approach","volume":"39","author":"Guo","year":"2012","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/humupd\/dmt058","article-title":"Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations","volume":"20","author":"Segars","year":"2014","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib21","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/PGP.0b013e318251035b","article-title":"Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate","volume":"31","author":"Williams","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib22","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMra1209993","article-title":"Uterine fibroids","volume":"369","author":"Bulun","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/14728222.2016.1180368","article-title":"Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies","volume":"20","author":"Wagenfeld","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib24","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/humrep\/dew140","article-title":"Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women","volume":"31","author":"Schutt","year":"2016","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib25","unstructured":"Chang X. Effects of progesterone receptor modulator vilaprisan on ovarian activity in healthy women. Poster 17, 3rd Congress of the Society of Endometriosis and Uterine Disorders Congress, Singapore,\u00a02017."},{"key":"10.1016\/j.fertnstert.2018.10.012_bib26","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/humupd\/dmw023","article-title":"Uterine fibroid management: from the present to the future","volume":"22","author":"Donnez","year":"2016","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.fertnstert.2013.10.051","article-title":"Validation of a new menstrual pictogram (superabsorbent polymer-c version) for use with ultraslim towels that contain superabsorbent polymers","volume":"101","author":"Magnay","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cct.2017.02.002","article-title":"Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator\u2013controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids","volume":"55","author":"Seitz","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib31","author":"Repros"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1208\/s12248-011-9304-7","article-title":"Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance","volume":"13","author":"Morris","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib34","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/1933719114549850","article-title":"The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids","volume":"22","author":"Pohl","year":"2015","journal-title":"Reprod Sci"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib35","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2174\/0929867321666141112122118","article-title":"Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs","volume":"22","author":"Kalgutkar","year":"2015","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13321-015-0053-y","article-title":"Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuries","volume":"7","author":"Liu","year":"2015","journal-title":"J Cheminform"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib37","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s40262-017-0607-4","article-title":"Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug-drug interaction potential","volume":"57","author":"Schultze-Mosgau","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib39","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.10.012_bib40","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","article-title":"The spectrum of endometrial pathology induced by progesterone receptor modulators","volume":"21","author":"Mutter","year":"2008","journal-title":"Mod Pathol"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028218321009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028218321009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:14:28Z","timestamp":1762150468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028218321009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0015028218321009"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2018.10.012","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vilaprisan in women with uterine fibroids: the\u00a0randomized phase 2b ASTEROID 1 study","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2018.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92018 The Authors. Published by Elsevier Inc. on behalf of the American Society for Reproductive Medicine.","name":"copyright","label":"Copyright"}]}}